Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations
Gregory M. Laird, C. Korin Bullen, Daniel I. S. Rosenbloom, et al.
Journal of Clinical Investigation (2015) Vol. 125, Iss. 5, pp. 1901-1912
Open Access | Times Cited: 375

Showing 1-25 of 375 citing articles:

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Ole S. Søgaard, Mette E Graversen, Steffen Leth, et al.
PLoS Pathogens (2015) Vol. 11, Iss. 9, pp. e1005142-e1005142
Open Access | Times Cited: 478
International AIDS Society global scientific strategy: towards an HIV cure 2016
Steven G. Deeks, Sharon R. Lewin, Anna Laura Ross, et al.
Nature Medicine (2016) Vol. 22, Iss. 8, pp. 839-850
Open Access | Times Cited: 402
Targeting the Latent Reservoir for HIV-1
Srona Sengupta, Robert F. Siliciano
Immunity (2018) Vol. 48, Iss. 5, pp. 872-895
Open Access | Times Cited: 314
Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing
Rafal Kaminski, Yilan Chen, Tracy Fischer, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 300
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression
Gilles Darcis, Anna Kula, Sophie Bouchat, et al.
PLoS Pathogens (2015) Vol. 11, Iss. 7, pp. e1005063-e1005063
Open Access | Times Cited: 261
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
Steven G. Deeks, Nancie M. Archin, Paula M. Cannon, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2085-2098
Open Access | Times Cited: 249
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
Julian Elliott, James McMahon, Christina C. Chang, et al.
The Lancet HIV (2015) Vol. 2, Iss. 12, pp. e520-e529
Open Access | Times Cited: 231
Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy
Carolina Gutiérrez, Sergio Serrano‐Villar, Nadia Madrid-Elena, et al.
AIDS (2016) Vol. 30, Iss. 9, pp. 1385-1392
Closed Access | Times Cited: 184
Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation
Guochun Jiang, Érica Araújo Mendes, Philipp Kaiser, et al.
PLoS Pathogens (2015) Vol. 11, Iss. 7, pp. e1005066-e1005066
Open Access | Times Cited: 181
Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells
Szu-Han Huang, Yanqin Ren, Allison S. Thomas, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 2, pp. 876-889
Open Access | Times Cited: 173
Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T cells
Emilie Battivelli, Matthew S. Dahabieh, Mohamed Abdel‐Mohsen, et al.
eLife (2018) Vol. 7
Open Access | Times Cited: 166
Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs
Amina Aït-Ammar, Anna Kula, Gilles Darcis, et al.
Frontiers in Microbiology (2020) Vol. 10
Open Access | Times Cited: 148
Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations
Judith Grau-Expósito, Laura Luque-Ballesteros, Jordi Navarro, et al.
PLoS Pathogens (2019) Vol. 15, Iss. 8, pp. e1007991-e1007991
Open Access | Times Cited: 146
Position effects influence HIV latency reversal
Heng‐Chang Chen, Javier P. Martínez, Eduard Zorita, et al.
Nature Structural & Molecular Biology (2016) Vol. 24, Iss. 1, pp. 47-54
Open Access | Times Cited: 158
CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs
Yonggang Zhang, Chaoran Yin, Ting Zhang, et al.
Scientific Reports (2015) Vol. 5, Iss. 1
Open Access | Times Cited: 154
Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells
Malika Hale, Taylor D. Mesojednik, Guillermo S. Romano Ibarra, et al.
Molecular Therapy (2017) Vol. 25, Iss. 3, pp. 570-579
Open Access | Times Cited: 153
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes
R. Brad Jones, Stefanie Mueller, Rachel W O’Connor, et al.
PLoS Pathogens (2016) Vol. 12, Iss. 4, pp. e1005545-e1005545
Open Access | Times Cited: 152
Novel Latency Reversal Agents for HIV-1 Cure
Adam M. Spivak, Vicente Planelles
Annual Review of Medicine (2017) Vol. 69, Iss. 1, pp. 421-436
Open Access | Times Cited: 151
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection
Jozef Stec, Oluseye K. Onajole, Shichun Lun, et al.
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 13, pp. 6232-6247
Closed Access | Times Cited: 150
HIV “shock and kill” therapy: In need of revision
Erik Abner, Albert Jordan
Antiviral Research (2019) Vol. 166, pp. 19-34
Closed Access | Times Cited: 142
Shocking HIV out of hiding
Thomas A. Rasmussen, Sharon R. Lewin
Current Opinion in HIV and AIDS (2016) Vol. 11, Iss. 4, pp. 394-401
Closed Access | Times Cited: 140
Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques
Lúcio Gama, Celina Monteiro Abreu, Erin N. Shirk, et al.
AIDS (2016) Vol. 31, Iss. 1, pp. 5-14
Open Access | Times Cited: 137
HIV Latency: Should We Shock or Lock?
Gilles Darcis, Benoît Van Driessche, Carine Van Lint
Trends in Immunology (2017) Vol. 38, Iss. 3, pp. 217-228
Closed Access | Times Cited: 137
HIV latency is reversed by ACSS2-driven histone crotonylation
Guochun Jiang, Don X. Nguyen, Nancie M. Archin, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 3, pp. 1190-1198
Open Access | Times Cited: 136
BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency
Lars Pache, Míriam Santos Dutra, Adam M. Spivak, et al.
Cell Host & Microbe (2015) Vol. 18, Iss. 3, pp. 345-353
Open Access | Times Cited: 132
Page 1 - Next Page

Scroll to top